Drugs / VG2062
VG2062
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07262164 | Mar 2026 → May 2027 expected | cancer | Virogin Biotech Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VG2062 | “A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid Tumors” NCT07262164 ↗ |
| Known as | Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection | “VG2062 is a Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection.” NCT07262164 ↗ |